Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

This is a prospective, multicenter, single-arm, open-label study. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX/GX for postoperative adjuvant treatment of pancreatic cancer.

Trial Details

NCT ID
NCT06389760
Phase
PHASE2
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Nimotuzumab
  • mFOLFIRINOX
  • GX
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • 1\. Age 18 years or older, gender unlimited;
  • 2\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • 3\. Had undergone complete macroscopic resection for pancreatic cancer (R0 or R1 resection) with histological confirmation and with no evidence of …
  • 4\. No prior tumor therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →